Friday, October 25, 2024
The RD Fund Announces Ocuphire
The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus Genetics, Inc. "Opus" (private) by Ocuphire Pharma, Inc., (
Wednesday, October 23, 2024
Ocuphire Pharma Merges with Op
Ocuphire Pharma ( (OCUP) ) just unveiled an update. Ocuphire Pharma has acquired Opus Genetics in an all-stock merger, forming a leading biotech company focused on gene therapies for inherited retinal
Wednesday, October 23, 2024
Ocuphire Pharma rating placed
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Wednesday, October 23, 2024
Ocuphire Pharma price target l
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Tuesday, October 22, 2024
Ocuphire Pharma Announces Acqu
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate sa
Tuesday, October 22, 2024
Ocuphire Pharma trading resume
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Tuesday, October 22, 2024
Ocuphire Pharma acquires Opus
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Tuesday, October 22, 2024
Ocuphire Pharma acquires Opus
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Tuesday, October 22, 2024
Ocuphire Pharma trading halted
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Monday, September 30, 2024
Ocuphire Pharma Announces Publ
Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profileFARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE)
Monday, September 30, 2024
Ocuphire Pharma Announces Publ
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Monday, September 30, 2024
Ocuphire Pharma announces publ
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.